$1.02
0.01%
(+0.00)
Previous close $1.02
NICI Rating

Latest Updates on CRBP

Loading Chart...

Latest Trading on NASDAQ

$1.02
0.01%
(+0.00)
Open 1.02
Previous Close 1.02
Today's Range
1.02 1.02
52 Week Range
0.91 4.00
Volume 1.26K
Avg. Volume (Weekly) 453.49K
Bid 1.02
Ask 1.03
Market Cap 127.74K
EPS -0.82
Shares Outstanding 125.23K
YTD High 4.00
Updated November 27, 2018

Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals is a pharmaceutical company working on therapies for inflammatory and fibrotic diseases. They are in the clinical stage of drug development for a subset of drugs that interact with the endocannabinoid system – the system in our bodies that responds to compounds in cannabis like THC and CBD.

No data to display.

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.